Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc89fce24341c88c7e7baa0e2aa4dea3a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc89fce24341c88c7e7baa0e2aa4dea3a NCIT_P378 "NCI" @default.
- Bc89fce24341c88c7e7baa0e2aa4dea3a type Axiom @default.
- Bc89fce24341c88c7e7baa0e2aa4dea3a annotatedProperty IAO_0000115 @default.
- Bc89fce24341c88c7e7baa0e2aa4dea3a annotatedSource NCIT_C73438 @default.
- Bc89fce24341c88c7e7baa0e2aa4dea3a annotatedTarget "A transforming growth factor beta2 (TGF-beta2) antisense gene-modified allogeneic tumor cell vaccine with potential immunostimulatory and antineoplastic activities. Belagenpumatucel-L is prepared by transfecting allogeneic non-small cell lung cancer (NSCLC) cells with a plasmid containing a TGF-beta2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent may elicit a cytotoxic T lymphocyte (CTL) response against host NSCLC cells, resulting in decreased tumor cell proliferation; vaccine immunogenicity may be potentiated by suppression of tumor TGF-beta2 production by antisense RNA expressed by the vaccine plasmid TGF-beta2 antisense transgene. Elevated levels of TGF-beta2 are frequently linked to immunosuppression in cancer patients and may be inversely correlated with prognosis in patients with NSCLC." @default.